Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma

Approved histone deacetylase (HDAC) inhibitors have low efficacy against the most commonly-diagnosed non-Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), but the mechanisms underlying clinical resistance are poorly understood. Using a DLBCL cell-based model, we previously demonstrated that r...

Descripción completa

Detalles Bibliográficos
Autores principales: Havas, Aaron P., Tula-Sanchez, Ana A., Steenhoek, Hailey M., Bhakta, Anvi, Wingfield, Taylor, Huntley, Matthew J., Nofal, Angela S., Ahmed, Tasmia, Jaime-Frias, Rosa, Smith, Catharine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597794/
https://www.ncbi.nlm.nih.gov/pubmed/37865047
http://dx.doi.org/10.1016/j.tranon.2023.101779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597794/
https://www.ncbi.nlm.nih.gov/pubmed/37865047
http://dx.doi.org/10.1016/j.tranon.2023.101779

Ejemplares similares